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Complement-Induced Post-Translational Regulation of TGF-ß Signaling on
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Kevin Liu and Dan Jane-Wit, MD/PhD. Section of Cardiovascular Medicine, Department of
Internal Medicine, Yale University, School of Medicine, New Haven, CT.

Abstract

Cardiac allograft vasculopathy (CAV) is a complex vaso-occlusive complication of heart
transplantation currently identified as a major limiting factor to long-term survival in those who
receive a cardiac transplant. In CAV, neointimal lesions form in graft vessels leading to ischemic
complications and ultimately allograft loss. CAV is medically untreatable and affects ~50% of
heart transplant patients. Endothelial cells (ECs) are a critical site where CAV lesions form, and
antibodies produced by the recipient that bind to donor HLA molecules on graft endothelium
(donor specific antibodies) have been identified as a key mediator in this process. Recent studies
have further identified a role for antibody-mediated complement fixation, specifically in
determining pro-inflammatory signaling changes induced through this process. The laboratory
of my mentor, Dr. Jane-wit, studies complement-mediated signaling in ECs and has previously
identified a signaling pathway implicated in CAV. In an unbiased assay to identify new
components of this pathway, I unexpectedly found that TGF-ß signaling molecules, canonically
understood to be anti-inflammatory, were involved in complement-induced EC activation.
During my thesis I defined a novel function for proteasomes as cellular chaperones to activate
TGF-ß signaling in response to complement activation. My thesis studies identify a pathologic
role for endothelial TGF-ß signaling in CAV.
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1. Introduction:

1.1 Heart Failure and Advanced Heart Failure: Prognosis and Treatment Modalities
Heart failure (HF) is a complex chronic and progressive syndrome resulting from
structural or functional impairments in ventricular filling or ejection of blood.1
Diagnosis is made clinically, and manifestations of HF include dyspnea and fatigue
limiting exercise tolerance and fluid retention leading to pulmonary and peripheral
congestion/edema.1 In the US, for those over 40 years of age, the risk of developing HF
is 20% with stable incidence.1 Prevalence of HF is estimated to be greater than 5 million
persons and increasing.1,2 The increasing prevalence in context of stable incidence is
thought to be due to evolving advancements in treatment options, including reninangiotensin-aldosterone antagonists, beta-blockers, and implantable cardioverterdefibrillators.2 A subset of those with HF are those with advanced or AHA Stage D HF
(refractory HF) requiring specialized interventions in any NYHA functional class.1
Etiologies vary from those with chronic HF and specific risk factors, such as diabetes
mellitus, obesity, hypertension, and chronic kidney disease, to acute major insults
(fulminant myocarditis, acute myocardial infarction with cardiogenic shock).2-5
Advanced HF is defined as persistent symptoms of HF despite optimal medical therapy
and is estimated to affect <1% to 25% of patients with heart failure with best estimates
being around 5% from the Acute Decompensated Heart Failure national registry
(ADHERE LM).2-4 Treatment for those with advanced HF is often limited to advanced
surgical HF therapies including left ventricular assist devices (LVADs) or cardiac
transplantation as those on optimal medical therapy were found to have extremely poor
prognoses as demonstrated in the medical arm (compared to LVAD) of the REMATCH
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(Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive
Heart Failure) trial.2,4,6 Specifically, survival at 1 and 2 years in the medical treatment
arm of advanced HF was found to be 25% and 8% respectively compared to 52% and
23% in the LVAD group.2,6 While innovations in LVAD technologies have significantly
improved since the REMATCH trial (especially centering around continuous flow
technologies), those who receive a transplant still have the best long-term course.2,7
Specifically, 1 and 2-year survival of those with LVADs is about 80% and 70% for
continuous-flow pumps (with recent multi-center retrospective studies citing 45%
survival to 4 years and mean survival of 4 year survivors to 7.1 years) while transplant
survival rates are between 85-90% at one year with median survival between 11-13
years.2,7-9 Thus again, while improvements in LVAD technologies as well as
understanding of LVAD parameters has overall improved prognosis in patients with
advanced HF, cardiac transplantation, where possible, remains the best option.
However, given the complexity of host immunity in response to donor allograft, much is
yet to be discovered/explained in the context of improving long-term sustainability of
cardiac allografts.

1.2 Cardiac Allograft Vasculopathy: A Target
While many advances in cardiac transplantation have been made over the years
in donor/recipient pairing, immunosuppression, and prevention and treatment of
nosocomial infections, cardiac allograft vasculopathy (CAV) is among the top three
causes of death in those who survive past the early post-transplant period (~6 months).
Nonspecific graft failure, acute rejection, and infection are major causes.10 CAV also
remains as the most common reason for post-transplant candidates to require re-
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transplant and is identified as a major limiting factor to longer survival in those who
receive cardiac transplant.10 Angiographic studies have indicated that CAV occurs in
42% of heart transplant patients at 3 years post-transplant while the more sensitive
intravascular ultrasonography (IVUS) has pitted estimates of up to 75% at 3 years.11
While CAV is the best studied in the realm of solid organ transplant and chronic
allograft changes leading to dysfunction, it is conceptually very similar to other chronic
post-transplant disorders in allograft vasculopathy (in renal transplantation),
bronchiolitis obliterans (seen in lung transplantation and in rare situations secondary to
inflammation), etc…11,12 Thus, CAV has been identified as a target for improving
outcomes in cardiac transplantation and may further have implications in improving
transplant outcomes in other fields as well.13 Moreover, understanding the
underpinnings of the immune-mediated response to allografts could yield valuable
information outside of the realm of transplant.
CAV is characterized by concentric fibrous intimal hyperplasia along the
transplanted epicardial and intramyocardial vessels leading to diffuse stenosis, tissue
malperfusion, ischemia, and ultimately graft loss.11,14 Changes can be seen as early as 6
months post-transplant as a mild intimal thickening with potential for mild fibrosis and
increase in extracellular matrix proteins.11 Due to the nature of CAV being diffuse and
non-focal as compared to focal atherosclerotic CAD, challenges have emerged in
diagnosis and treatment. Specifically, traditional angiographic techniques have
difficulties in picking up focal areas of stenosis (in attempting to compare proximal vs
distal diameters/pressures) and angioplasty or stents are not able to be implemented as
there is no focal plaque/atheroma or area to target.11 Furthermore, no medical therapies
have been identified or developed to ameliorate or halt the progression of CAV.15,16
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Current therapies are all based on consensus expert opinion (level of evidence C) and
typically involve modification of the immunosuppressive regimen to include mTOR
inhibitors rather than anti-metabolites, but much work is ongoing in identifying targets
and understanding underlying pathophysiology of CAV.17 Thus, there is an urgent need
to better understand CAV to develop more specific and effective therapies.

1.3 Pathophysiology of CAV
Early studies on CAV sought to delineate the roles that classical atherosclerotic
risk factors (hyperlipidemia, diabetes, HTN, etc…) had to play in post-transplant
coronary arterial disease.18 These early studies found CAV to be clinically distinct from
CAD due to atherosclerosis, and identified an immunological component to allograft
vasculopathy/CAV.11,18 Further analysis and studies of pathological samples of CAV
tissue indicated some potential similarity between CAV and atherosclerotic disease in
the presence of an immune reaction, but identified differences in the primary antigen
driver.13,18 In CAV, pathological areas of intimal hyperplasia were found to respect
suture lines separating host from donor, indicating that the primary driver may be MHC
incompatibility on luminal endothelial cells as opposed to oxidized LDL in the subendothelium as seen in classic atherosclerosis.13 As such, CAV is often refractory to
agents aimed at treating CAD, though superimposed effects of atherosclerosis on CAV
may contribute in certain situations.12,15 Studies performed in immunodeficient mice
with implanted human coronary artery segments implicated interactions between
transplanted donor endothelial cells (presenting MHC antigens) and host T cells
(producing cytokines) as central to CAV.13,19 Specifically, IFN- γ was identified as a key
mediator of intimal expansion and CAV in this model.13,19 IFN- γ was found to both
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induce expression of MHC I and II on arterial endothelial cell surfaces (which they are
minimally expressed to non-expressed in its absence) and lead to arteriosclerotic
changes in causing intimal expansion.19 Both innate and adaptive immunity were
identified as contributing to CAV, however, the role of innate immune mediators such as
natural killer (NK) cells appear to be dependent on the adaptive immune stimulus as, in
their absence, NK cells alone do not produce CAV-type lesions in transplanted allografts
in B and T-cell immunodeficient mice (scid mice).14 However, other studies have posited
a role for innate immune cells in responding to cellular injury in ischemia-reperfusion
injury and cellular necrosis.12 The role of the innate immune response thus is posited to
be immunomodulatory in nature.12-14
Initial observational studies in CAV have indicated a higher risk of developing
CAV in patients who develop donor specific antibodies (DSA) that are reactive with nonself MHC molecules expressed by donor endothelial cells.13 Numerous studies have
correlated higher DSA levels +/- the presence of complement deposition to worse
outcomes in both survival and/or graft dysfunction due to CAV, potentially establishing
a relationship between the two and identifying DSA as a potential lead as a therapeutic
target.17 Immunohistochemical analyses of endomyocardial biopsies and serological
studies in post-transplant grafts reveal DSA correlates with C4d complement protein
deposition and worsened outcomes in the presence of both C4d and C3d deposition
(indicating progression down the complement cascade).14,17,20 From these observations,
C4d is used as a diagnostic marker for antibody mediated rejection (AMR) on
endomyocardial biopsy due to the fact that it has a long half-life and is covalently
bonded to the surface of arterial endothelial cells.20 One accepted pathway by which
DSA mediates damage to graft vasculature is by binding to foreign MHC antigens on
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allograft endothelium (with evidence that DSA against class I and class I+II lead to
worse outcomes)20 and fixation of complement via classical pathway including
components C1q, C4b, C4d, C3a, C3d, and C5 leading to endothelial cell injury and
inflammation.21 Studies have shown in vivo that antibodies targeting MHC I can
provoke graft arteriosclerosis in immunodeficient scid/beige mice potentially indicating
the primary target of DSA in causing CAV.22

1.4 Current Management Recommendations for CAV
As above mentioned, no level I recommendations exist for treating AMR.17
Current therapies for CAV center around the principles of modulation and suppression
of immune-mediated injury as well as providing supportive therapy for allograft heart
failure. Traditional immunosuppressive techniques including corticosteroids,
calcineurin inhibitors (tacrolimus, cyclosporine), mTOR inhibitors (rapamycin,
sirolimus), and anti-proliferative agents [azathioprine, mycophenolate mofetil (MMF)]
targeting B and T cells are often included in managing AMR, though systematic studies
have not been performed studying their efficacy.17 As DSA has emerged as playing a
central role in invoking chronic allograft rejection, targeting circulating alloantibodies
via plasmapheresis in combination with other immunosuppression techniques
(corticosteroids, MMF, cyclophosphamide, etc…) have been implemented in small
studies indicating some potential efficacy.17,23 Inhibition of circulating alloantibodies via
IVIg therapy combined again with other immunosuppressive agents has also been
utilized in small case series with reversal of rejection, but also with high incidence of
recurrence.17,24 In targeting B cell populations specifically, rituximab, an antibody
engineered to target B cell surface marker CD20, has been used in small case series as
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monotherapy as well as salvage therapy with good success and has been found to
desensitize transplant candidates who have high reactivity against a standard panel of
HLA subtypes (high panel reactive antibody activity).17,25 As CD20 is not expressed on
mature plasma cells, the primary alloantibody-producing cell, bortezomib and
carfilzomib, proteasome inhibitors used in multiple myeloma to deplete plasma cells,
have been trialed with successes leading to ongoing phase II clinical trials.17,26,27
Specifically, a study in children receiving renal transplants showed stabilization of grafts
in C4d positive antibody mediated rejection using bortezomib.28 Larger studies centered
around using bortezomib in adult renal transplant recipients are ongoing in a Phase II
trial through the BORTEJECT Study.26 Last, as C4d and complement are also implicated
in the pathogenesis of CAV, it has been raised as a target as well. Eculizumab, a terminal
complement inhibitor used in paroxysmal nocturnal hemoglobinuria, has been studied
in preclinical trials in rats and murine models as successfully able to prevent antibody
mediated rejection in renal and cardiac transplantation, and one report of utilization of
eculizumab as salvage therapy was successful in a patient undergoing AMR of a kidney
transplant, but a larger study in the renal transplant community showed no differences
after 1 year with eculizumab treatment (though it was found to decrease acute clinical
antibody-mediated rejection).17,29-31 Again it is noted that current therapies for CAV are
limited, with medical therapies for CAV limited to switching or increasing
immunosuppression, and more invasive options including LVADs, PCI (if focal area to
target), or re-transplantation.

1.5 Complement as an Active Area of Study
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While the presence of C4d is used clinically as a diagnostic marker for AMR, the
specific role that complement plays is an area of active study. Complement proteins
(synthesized in the liver) function in a series of biochemical conversions in the realm of
innate immunity and, in the setting of DSA fixation, initiate the complement cascade
culminating in MAC formation via the classical pathway. In this pathway, immune
complex deposits (IgG or IgM) on the cell surface expose complement binding sites on
the constant portion (Fc) of the antibody leading to a conformational change of the C1
complex, in turn activating C4, then C2, to create the C3 convertase (C4b2a).32,33 This, in
turn, activates C3, leading to creation of the C5 convertase (C4b2a3b) ultimately leading
to downstream creation of the membrane attack complex (MAC), composed of C5b, C6,
C7, C8, and polymers of C9.32,33 This terminal complex classically functions via osmotic
and ion flux, creating pores on the surface of cells leading to rapid influx of water and
ions.34 However, in nucleated cells and in human cells, numerous protective elements
exist in order to prevent rapid lytic destruction, a process called homologous
restriction.35 CD59, a cell surface glycoprotein, regulates terminal complement
formation by inhibiting C9 (the final complement protein) from assembling the inner
core of pores that are formed by the MAC complex. It is well studied as being defective
in paroxysmal nocturnal hematuria, a genetic deficiency of CD55 or decay accelerating
factor (DAF).34 Presence of ion pumps, though they require energy, can also help to
stabilize the cell in temporizing and maintaining ion gradients.34 MAC complexes are
also able to be endocytosed into the cell or ectocytosed via budding.34 While these frank
lytic effects of MAC are often avoided in nucleated human cells, studies have shown that
assembly of terminal complement structures on different cell types can lead to various
signaling changes leading to cell cycle alterations, protein synthesis modifications, and
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inflammatory changes.34 These studies have indicated that at least three potential
pathways for signaling exist. First, while ion pumps may maintain membrane integrity,
rapid calcium influx due to the large extracellular concentration may lead to modulation
of calcium-binding proteins activating downstream effectors, though some of these
changes have been observed in a low-extracellular calcium environment indicating
possible calcium-independent pathways.34 Studies have suggested that the MAC itself
may interact with G-protein binding motifs as well as TLRs and other signaling
receptors on the cell surface, though no formal structure or function has been
elucidated.34,36-38 Finally, the inhibitory CD59 GPI-anchored protein and other GPI
anchored proteins could also initiate downstream signaling pathways via clustering by
binding to MAC complexes, though this pathway of MAC-CD59 inducing signaling is
still being elucidated.34 Thus, while complement’s role in CAV is established as being a
downstream component of DSA fixation, the specific mechanism by which it acts in both
CAV as well as more generally in cellular processes is an area of active study.

1.6 Developing a Model and System to Study DSA and Complement
A challenge associated with studying in vitro and in vivo DSA-mediated
complement fixation on human endothelial cells is the specificity DSA have for a specific
HLA molecule (namely those found on the allograft).39 As a surrogate to DSA, polyclonal
mixtures of antibodies with wide reactivities to a standard panel of HLA antigens, or
highly reactive (generally >80%) panel reactive antibodies (PRA), have successfully
been able to mimic the effects of DSA binding to a specific HLA surface molecule.39,40
These polyclonal antibodies were found to successfully deposit on human endothelial
cells with fixation of complement proteins potentiating EC-mediated activation of T-
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cells.39 Consistent with the variety of studies regarding terminal complement’s effects on
nucleated human cells as aforementioned, PRA deposition on endothelial cells led to
downstream complement fixation and activation on cell surfaces which, instead of
causing lysis, ultimately induced increased transcription of pro-inflammatory
mediators.39 These effects reproduced clinical observations where abundant
complement deposition occurs in target vascular beds that show perivascular immune
cell infiltrates in the absence of widespread vascular necrolysis.39,41 Moreover, the above
effects of PRA sera containing entirely human-derived components were not seen in
other studies incorporating xenogeneic complement components, e.g. antisera, to
experimentally induce complement activation.
In using PRA sera to induce terminal complement activation, i.e., MAC assembly,
three principal mediators of EC activation were identified, namely DSA, anaphylatoxins,
and MAC.12,39,41 In prior studies involving fractionation and recombination of PRA sera
and complement-deficient human reference sera, MAC was found to induce EC
activation, characterized by upregulation of chemokines, cytokines, and adhesion
molecules.12,39,41 In interrogating the transcriptional and molecular changes associated
with this response, it was found that the non-canonical NF-kB pathway was being
activated by MAC.39 Notable findings in these early studies were that the molecular
changes associated with non-canonical NF-kB signaling were both rapidly inducible
(changes seen within 30 minutes) and durable (changes lasting up to weeks).39,41 These
findings were inconsistent with the classically described non-canonical NF-kB signaling
modality in which changes require ~8 hours in order to be detected.41 Further work
indicated that PRA-dependent MAC activation of non-canonical NF-kB functioned
through a novel endosome signaling pathway, utilizing Rab5+ endosomes as opposed to
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previously held beliefs that signaling occurred from the cell surface due to calcium flux
as aforementioned being described as one of three potential pathways by which
complement signaling may occur (calcium-dependent pathway).41 The terminal
complement MAC were found to be endocytosed via clathrin-mediated endocytosis into
the cell while localizing to Rab5+ endosomes.41 Rab5 itself is a small GTPase that
mediates downstream functions through recruiting effector proteins and is a marker of
early endosomes.42 Ultimately, a Rab5 endosome effector protein ZFYVE21 was
identified as an inducible effector that serves to modulate the endosome membrane lipid
content in order to recruit members of the non-canonical NF-kB family in order to
potentiate signal activation.42 Specifically, ZFYVE21 was found to promote SMURF2mediated polyubiquitinylation and proteasome degradation of endosome-associated
PTEN in order to induce endosome-membrane enrichment of PI(3,4,5)P3 in order to
recruit activated Akt and NF-kB-inducing kinase (NIK) leading to non-canonical NF-kB
activation.41,42 In follow-up studies performed subsequent to my thesis studies, the
Jane-wit lab found that Rab5-associated NIK induced recruitment of inflammasome
components including NLRP3 and caspase-1 from the ER and cytosol respectively, and
that apposition of these molecules on Rab5 endosomes caused NLRP3 inflammasome
activation, a process leading to EC release of IL-1b. 38,43 IL-1b was then found to activate
canonical NF-kB.38,43
Thus, the pathway as described currently in the literature functions through the
following steps: DSA (modeled by PRA) binds to MHC molecules on allograft luminal
endothelial cell surfaces and affix complement proteins via the classical pathway.41,42
Terminal complement forms and these MAC are endocytosed into the cell via clathrinmediated endocytosis where they co-localize to Rab5+ endosomes.41,42 This, in turn
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leads to effector protein ZFYVE21 being recruited, activating the ubiquitin ligase
SMURF2.41,42 SMURF2 marks PTEN in the endosome for degradation, altering the
endosome membrane content to include higher concentrations of PI(3,4,5)P3 to recruit
activated Akt which activates NF-kB inducing kinase which leads to downstream NF-kB
signaling.41,42 ZFYVE21 was detected in a variety of patients with complement-mediated
disease including transplant rejection, and a bioinformatics search identified a drug
inhibitor of ZFYVE21, miltefosine, that blocked CAV in a humanized mouse model.42

Interestingly, in interrogating changes associated with this pathway of induction
of ZFYVE21, MG132, a pan-proteasome inhibitor, was found to induce a similar
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repertoire of changes associated with PRA-induced MAC deposition on endothelial cell
surfaces, upregulating ZFYVE21 and inducing NIK downstream in a similar fashion
suggesting a potential role for proteasomes in initiating this pathogenic pathway.42

1.7 Rab5 and the Rab Protein Family
Rab proteins form the largest branch of the small GTP-binding proteins,
commonly referred to as small GTPase proteins, that have an essential role in vesicular
transport in eukaryotic cells.44-46 Rab proteins structurally form one of at least 5 families
of small GTP-binding proteins including Raw, Rho, Rab, Sar1/Arf, and Ran, in total
constituting over 100 members with over 50 Rab proteins having been identified so
far.45 Identified Rab proteins have been shown to be ubiquitous in eukaryotic cells,
though there are certain Rab proteins that are cell-type or tissue specific.44 They, along
with other small GTP-binding proteins, cycle between a GDP-bound off-state and GTPbound on-state that is catalyzed by guanine exchange factor (GEF) proteins, however, it
is noted that Rab proteins have been found to bind to effector proteins to some degree
even in their “inactive” GDP-bound state.44,46 Rab proteins have been found to cluster in
membrane compartments on live-cell microscopy, establishing distinct microdomains.46 Furthermore, Rab proteins have been found to act through recruitment of
effector proteins as well as other Rab proteins through specific GEF proteins in order to
facilitate an organized cascade of downstream events.44,46 Due to their distinct
localization patterns and specificity for establishing micro-domains, Rab proteins
initially were thought to function as markers for transport, ensuring vesicles leaving one
compartment would arrive at a correct destination.44 However, ongoing research has
identified Rab proteins binding to effector proteins with very diverse functions,
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implicating them in a larger scheme of intracellular signaling and transport.44,46 Rab5
specifically has been identified as an early endosomal marker generally composed of
smaller endosomes that, in a typical progression from early to late endosomes, undergo
fusion events leading to fewer, larger endosomes with loss of Rab5 and acquisition of
Rab7, a marker of late endosomes.47 While their role as early endosome markers may be
diverse, their apparent dynamic, but consistent expression on early endosomes prove to
be useful as a consistent target in order to identify effector proteins associated with
these early endosome populations following endocytosis of MAC on endothelial cell
surfaces. Rab5 effectors including Rabaptin-5 and certain PI3 kinases initiate a myriad
of downstream functions.44-46,48 ZFYVE21, identified in the studies above, specifically
and directly bound to Rab5-GTP complexes but not Rab5-GDP and initiated
inflammatory signaling, thus operationally qualifying this protein as a Rab5 effector.42

1.8 Proteasome Structure and Function
The proteasome, with known functions in the MAC fixation pathway as targeting
PTEN for degradation through the ubiquitin-proteasome pathway is regarded as the
principle proteolytic machinery of the cell. Briefly, proteasomes have a core proteolytic
element (20S core particle) in a cylindrical orientation that is sandwiched between one
or two regulatory particles on either side (19S regulatory particle being the most well
studied).49,50 The regulatory particle is thought to confer a degree of specificity for the
core proteolytic element, binding to poly-ubiquitylated substrates and regulating the
opening of the core proteolytic element to degradation of proteins.49,50 Different
ubiquitin signals and conformations are thought to confer preference to the proteins
that are allowed passage through the core proteolytic element of proteasomes and in
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general, polyubiquitin chains have higher affinity compared to monoubiquitinlyated
proteins.49,50 Proteasomes also play a key role in classically described NF-kB activation
in both canonical and non-canonical pathways.49,50 Specifically, ubiquitin-mediated
degradation is required for degradation of the NF-kB inhibitor IkB (generally classified
in the canonical pathway) and plays a critical role in targeting NF-kB precursors p105
and p100 (p100 targeting classified in the non-canonical pathway) for proteasomal
processing into mature forms p50 and p52.51,52 Ubiquitination has also been found to
play a role in NF-kB protein kinase function independent of proteasome function.51,52
Thus, both canonical and non-canonical NF-kB activation require proteasome
degradation of regulatory elements in order to allow for transcriptional activation.49-52
There have been recent interests in the clinical use of proteasomes inhibitors thought
previously to be too cytotoxic for systemic use. FDA-approved proteasome inhibitors
including bortezemib and carfilzomib have been used in numerous clinical settings
including CAV.14,26,53

1.9 NF-kB Signaling Pathway (Canonical, Non-Canonical, and Non-classical NonCanonical)
Nuclear factor found near the kappa segment of B cells (NF-kB) was initially
discovered by the Baltimore lab as a rapidly inducible transcription factor since found to
have broad implications in a diverse set of cellular responses ranging from inflammation
to oncogenesis. The NF-kB signaling pathway effector proteins consist of 5 family
members p50, p52, Rel A (p65), Rel B, and c-Rel which all function through binding to
promotor/enhancer sites of target genes regulating transcription by recruitment of
activator and repressor proteins.54-57 At baseline, these effector proteins reside in the
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cytoplasm in inactive forms, bound to above-mentioned inhibitory IkB proteins.54-57
Upon activation, the IkB protein is marked for degradation by proteasomes often after
phosphorylation by a IkB kinase complex and the active NF-kB proteins heterodimerize
and translocate to the nucleus to modulate expression.54-57
In studying activation of the NF-kB pathway, there classically has been a
distinction between the “canonical” and “non-canonical” pathways based on the triggers
as well as pathway mediators.54-57 In the canonical NF-kB pathway, microbial products
activating toll-like receptors (TLRs) or pro-inflammatory cytokines like TNF-⍺ or IL-1
leads to activation of IkB kinase complexes by TRAF/RIP complexes inducing
phosphorylation and degradation of inhibitory IkB⍺ releasing NF-kB dimers which
translocate to the nucleus.54-57 In the non-canonical or alternative pathway (described
mostly in lymph-organogenesis as well as B-cell activation), TNF-family cytokines
(excluding TNF-⍺), CD40L, RANKL and B-cell activating factor leads to activation of
IkB kinase complexes through TRAFs and NF-kB-inducing kinase (NIK) leading to
proteasomal processing of p100 to p52.54-57 Classically in non-canonical NF-kB
signaling, NIK levels increase slowly over several hours and are correlated with
degradation of TRAF3 (through ubiquitination).39,41,54-57 What has been observed in
DSA-mediated complement signaling on endothelial cells, however, is that there is a
rapid induction of NIK that is not correlated with TRAF3 degradation and the levels are
durably elevated for weeks after PRA treatment indicating a non-classical model of noncanonical NF-kB induction.39,41 As previously described, phosphorylated Akt upstream
of NIK plays a central role in this rapid induction and the ZFYVE21 pathway modifies
the Rab5 endosomal lipid landscape (via PTEN) in order for phosphorylated Akt to be
recruited.39,41,42
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1.10 TGF-ß Signaling Pathway and SMURF2
The TGF-ß family of proteins are nearly ubiquitously expressed in all cell types,
including endothelial cells, and play key roles in growth, differentiation, and tissue
morphogenesis.58 TGF-ß signaling occurs primarily through surface complexes of Type I
and Type II receptors and their downstream effector Smad proteins that exist in three
subgroups encompassing R-Smads, Smad4 in vertebrates, and I-Smads.58,59 Notably,
TGF-ßRI is ubiquitously expressed on cells.60 The signaling cascade is described as the
following: ligand binding or a type III receptor presentation leads to TGF-ßRII (Type II
receptor) that is constitutively active recruiting TGF-ßRI (Type I receptor) to form
heterodimers.58,59 Following complex formation between type I and II receptors, the
active TGF-ßRI phosphorylates and activates downstream Smad2 and Smad3 which
ultimately oligomerize with a common Smad4 to translocate to the nucleus to regulate
expression of target genes.58,59 Again, the roles of TGF-ß are complex and varied, and its
role in novel signaling pathways are still being elucidated, though canonically, TGF-ß
signaling has been shown to mediate anti-inflammatory effects in T cells, B cells, and
macrophages, with the role of this signaling pathway in CAV unknown.61
As previously described above, proteomic analyses of FACS-sorted MAC+Rab5+
endosomes showed a reduction in spectral counts for PTEN, a PI(3,4,5)P3 phosphatase
that functionally acts as an Akt inhibitor.42 Prior studies showed that the MAC induced
loss of PTEN from MAC+Rab5+ endosomes and that PTEN was inducibly
ubiquitinylated and targeted by proteasomes for degradation.42 To identify E3 ubiquitin
ligases that could mediate this process, we looked at the literature for other proteins that
could ubiquitinylate PTEN and found that 2 of these proteins were in the NEDD4
family, consisting of 9 proteins.42,62-66 Of these, the Jane-wit lab identified SMURF2 as a
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mediator of PTEN ubiquitinylation.42 SMURF2, or Smad ubiquitin regulatory factor 2, is
a type E3 ubiquitin ligase located primarily in the nucleus that has been best studied in
its role as a regulator of the TGB-ß signaling pathway.67-69 Classically, SMURF2, similar
to its related isoform, SMURF1, has been characterized as a negative regulator of TGF-ß,
translocating out of the nucleus in response to TGF-ß receptor activation, binding to ISmads (inhibitory Smads) to ubiquitinate TGF-ß type I receptors leading to their
proteasomal degradation to attenuate the TGF-ß signal.67-69 However, SMURF2 has
been found to play a role in numerous other capacities including tissue homeostasis,
genomic stability, and even in tumorigenesis (as opposed to its classically studied and
accepted role in tumor suppression).67-69 In the DSA-induced complement signaling
pathway, SMURF2 retains its ubiquitin ligase role in ubiquitinating PTEN on the Rab5
endosomal surface, leading to its degradation in order to influence the endosomal lipid
content for downstream recruitment of effectors.42

2. Statement of Purpose:

As highlighted above, a potential link between antibody-mediated complement
fixation has been established with CAV through the MAC-induced ZFYVE21 signaling
pathway leading to downstream non-canonical NF-kB induction. To understand the
nature by which this novel pathway of non-canonical NF-kB is activated, the focus turns
to the means by which the downstream pro-inflammatory signaling proteins are
induced on the Rab5+ endosomal membrane.
In terms of protein induction, two general pathways can be considered:
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A. “Slow pathway” involving
transcription and translation
leading to gradual protein
accumulation in hours.
B. “Rapid pathway” involving protein
activation (phosphorylation by
kinases, cleavage, etc…) or rescue
from basal degradation (basally
transcribed, translated, and
ubiquitinated for degradation by
proteasomes under homeostatic
conditions).

A notable finding in the early studies of the DSA-mediated complement signaling
pathway was the rapid nature (within 30 minutes) by which the NF-kB proinflammatory signaling proteins were induced. Furthermore, prior to induction, these
proteins were not found in either their active or inactive states. Thus, it is hypothesized
that these stress-related proteins are basally ubiquitinated and degraded by
proteasomes while in homeostatic conditions, and in response to stressors like
complement deposition, are rescued from proteasomes to rapidly accumulate to
perform their effector function. As noted in the literature described above, proteasomes
are known to have some degree of specificity as conferred through their lid element, and
the pan-proteasome inhibitor MG132 was found to induce similar changes as DSAmediated complement signaling.
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After induction or rescue of these stress-related proteins, it is posited that the
proteins are recruited or localized to a common signaling platform of Rab5+ endosomes
where they are stabilized and positioned in proximity to each other to perform their
downstream signaling function. Rab5+ endosomes were found to be a centralized
location in which the initial components of DSA-mediated complement signaling were
found.
The initial aim of my study was to identify other proteasome-mediated molecules
like ZFYVE21 that were recruited to Rab5 endosomes to activate NF-kB. During the
course of my studies, I unexpectedly uncovered a role for TGF-ß signaling in CAV, and I
redirected my study to understand how this pathway became activated and how it
mediated CAV.

3. Hypothesis:

Antibody-induced complement activation post-translationally sequesters proinflammatory signaling proteins on Rab5+ endosomes following a two-step model:
1. Inhibition of a proteasome population leads to rapid up-regulation of
inflammation-related proteins.
2. After rescue, inflammatory proteins are recruited to Rab5 endosomes in
order to perform effector function.

4. Methods:

*Student independently performed
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**Student performed parts of experiment
***Performed by other members of lab

Endothelial Cell Culture and Treatment*: Human umbilical vein endothelial cells
(HUVEC) obtained as de-identified tissue discarded from the Department of Obstetrics
and Gynecology at Yale New Haven Hospital were plated in gelatin-coated flat bottom
culture flasks, dishes, or multi-well plates (BD Biosciences, San Jose, CA) with
Endothelial Cell Growth Medium-2 (EGM-2MV) containing 20% FBS, hydrocortisone,
hFGF-B, VEGF, IGF-1, ascorbic acid, hEGF, and GA-1000 (Lonza Bioscience). Cells
were serially cultured at 37°C with 5% CO2. All experiments in this manuscript were
performed with cells at passage levels 2-6 at which point such cultures are free of
contaminating leukocytes and uniformly express EC markers. To split the cells and/or
plate for culture, trypsin-EDTA (0.25%) was used to dissociate the adherent cells from
the vessel. Cells were trypsinized for no more than 60 seconds. Cells were plated at an
ideal concentration of 10,000 cells in 200 µl. Discarded high-titer PRA sera were
obtained as de-identified samples from Yale-New Haven Hospital's tissue typing
laboratory and showed >80% reactivity to either HLA class I and/or II antigens. PRA
sera underwent endotoxin testing according to manufacturer!s specifications (Sigma)
and human viral pathogen testing under h-IMPACT testing protocols (IDEXX RADIL,
Columbia, MO). Prior to PRA treatment or in control groups for PRA treatment, HUVEC
were pre-treated for 48-72 hours with IFN- γ (50ng/mL, Invitrogen, Grand Island, NY)
in EGM-2 medium prior to addition of a 1:10 dilution of a PRA positive serum in gelatin
veronal buffer (Sigma, St. Louis, MO) for the indicated times. For MG132 treatment,
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MG132 (25 µM, Selleck Chemicals) was added to EGM2 media for the indicated times at
the indicated concentration of 1:1000.

Western Blotting/Analysis*: Expression levels of intracellular proteins were
quantified by western blotting. To do so, EC monolayers grown to 80-90% confluence
from C6 or C12 wells (BD Biosciences, San Jose, CA) were washed in ice cold PBS three
times and lysed in RIPA buffer (Sigma). Samples were then mixed with Laemmli's
sample buffer, heated at 95°C for 10 minutes, and loaded at 30µg per lane. After
electrophoretic resolution, samples were transferred onto a PVDF membrane (EMD
Millipore) for two hours at room temperature. Membranes were blocked with 5% BSA
and primary antibody was added at 1:1000 dilution overnight at 4°C while rocking
gently. Primary antibodies were all used at 1:1000 dilution and included ZFYVE21
(Novus Biologicals), SMURF2 (Cell Signaling Technology), NIK (Cell Signaling), active
Rab5 (NewEast Biosciences), Rab5 (Santa Cruz Biotechnology), TGF-ßRII (R&D),
smad2 (R&D), smad3 (R&D), p-smad2/3 (R&D), TGF-ßRI (R&D), PSME4 (Abcam),
PSMD3 (Abcam), KIAA0368 (Abcam), PSME1 (Bethyl), PSMF1 (Bethyl), PSMB8
(Bethyl), PSMA2 (Bethyl), PSMC2 (Bethyl), Rubicon (Cell Signal), and β-actin (Sigma).
Anti-mouse and anti-rabbit horse radish peroxidase (HRP)-conjugated antibodies
(ThermoScientific, Waltham, MA) were then added at room temperature for one hour at
a dilution of 1:1000 and bound HRP was visualized using chemiluminescent developing
of probed membranes on X-ray film (Denville Scientific, Metuchen, NJ) as per
manufacturer!s specifications (SuperSignal Pico West, Pierce, Junction City, OR).
Densitometry was performed using NIH Image J software (Bethesda, MD).
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Co-Immunoprecipitation**: For co-IP experiments, 20 µL protein A/G beads
(ThermoFisher) were incubated with 10 µL Rab5 antibody, PMSC2 antibody, or PSMA2
antibody at 4 °C overnight. Rab5 antibody (1 µg, abcam) and protein lysates (10ug) were
incubated at 4 °C overnight (Pierce). Antibody-conjugated beads. The next day,
antibody-bound lysates were mixed with agarose protein A/G beads. The beads were
washed and resuspended at a volume of 32 µL using RIPA buffer (Cell Signaling). For
western blotting, following the incubations, Laemli!s buffer (12 µL) and 1 mM
dithiothreitol (6 µL) were then added to samples, heated for 95 °C for 13 min, and
subjected to western blotting. Antibodies used for western blotting were all used at
1:1000 dilution as described above. For proteomics analysis, after elution of protein,
labeled samples were sent to Yale Proteomics lab (The Mass Spectrometry (MS) &
Proteomics Resource of the W.M. Keck Foundation Biotechnology Resource
Laboratory).

Transfection of Rab5 Constructs***: Rab5-GFP WT and DN constructs were gifts
from Dr. Michael Simons (Yale University School of Medicine, New Haven, CT). To
transfect plasmids, ECs at 60– 70% confluency in 24-well dishes were pretreated with
IFN-γ as above for 48 h, followed by transfection of dynamin or Rab5 WT and DN
constructs using lipofectomy. Then 500 ng of each construct was mixed with 0.4 µL of
PLUS reagent (Invitrogen) in 200 µL/well of Opti-MEM for 5 min at room temperature,
followed by the addition of 1.5 µL of Lipofectamine 2000 (In- vitrogen) for 30 min at
room temperature. This mixture was added to cultured HUVECs at 37 °C for 8 h,
followed by washing and buffer exchange with EGM2-MV medium. Using this protocol,
∼30–50% of ECs remained viable for analysis. The transfection efficiency calculated

24 of 53

using flow cytometry measuring GFP fluorescence was typically >45%. GFP+ ECs were
then sorted and replated to yield homogeneous cultures carrying each respective
construct.

siRNA transfection of EC**: HUVECs were pretreated with IFN-γ for 48hrs prior to
siRNA transfection. siRNA (Dharmacon, Waltham, MA) targeting PSMC2 or nontargeting siRNA (target sequence UAA CGA CGC GAC GAC GUA A) were purchased
commercially (Dharmacon) and transfected into HUVECs at ~60–70% confluency in
24-well plates (BD Falcon). siRNAs were diluted at 40 nM concentration in Opti-Mem
culture media (Gibco) and mixed at equal volume with RNAiMax transfection reagent
(Invitrogen) diluted 1:50 in Opti-Mem for 45 min at room temperature. This mixture
was then added to HUVEC cultures at 37 °C for 6 h prior to washing and buffer
exchange with EGM2-MV. Cells were then analyzed by western blots 72 h after
transfection.

Statistical methods*: Statistical analyses were performed using the computer
software “Origin” (Origin, Northampton, MA). Absolute numbers and percentages of
vesicles were analyzed by Student!s t test and Chi-squared analyses, respectively. p
values < 0.05 were considered statistically significant. Multiple comparison analyses
were performed using analysis of variance. Standard deviations are reported throughout
the text. References using the ImageJ image analysis software (Bethesda, MD) with the
Just Another Colocalisation Plugin (JACoP).
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5. Results:

5.1 Proteomics Screen to Identify Rab5+ Endosome-Sequestered Proteins
Given the central role that the Rab5+ early endosome population plays in the
DSA-mediated complement signaling pathway, our focus initially centered on searching
for and identifying pro-inflammatory signaling proteins that are post-translationally
sequestered on Rab5+ endosomes in response to DSA. As Rab5 is ubiquitous on these
endosomes, our strategy was to use Rab5 to perform co-immunoprecipitation to pull
down endosomal populations of interest, elute peptides from said endosomes, and
perform proteomic analysis to interrogate the effector proteins that are recruited to
these endosomes (Figure 3). Specifically, we cultured five groups of human umbilical
vein endothelial cells (HUVEC) with experimental Rab5 construct groups and treatment
groups. The five groups were Rab5DN (constitutively inactive) control, Rab5Q79L
(constitutively active) control, Rab5Q79L (constitutively active) with MG132 panproteasome inhibitor, Rab5Q79L (constitutively active) with PRA treatment for 4 hours,
Rab5WT (wild type) with PRA treatment. Both Rab5DN and Rab5Q79L groups were
used as controls to identify the
spectrum of proteins normally
recruited to Rab5 endosomes under
homeostatic conditions. The
Rab5Q79L group with MG132 was
used in order to screen for proteins
that are nonspecifically rescued
from proteasomal degradation and
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recruited to active Rab5 endosomes. The Rab5Q79L group with PRA treatment served to
comb through pro-inflammatory proteins rescued from degradation and recruited to
active Rab5 endosomes. Last, the Rab5WT group with PRA treatment mimics the
pathophysiological response to DSA binding onto allograft transplant vessels and to the
DSA-mediated complement fixation pathway.
From this proteomics screen, 1956 unique proteins on Rab5 endosomes were
identified and categorized based on their known associated pathways (Figure 4).
Notably, 494 unique proteins were found to be in common between all 5 groups. The
Rab5WT-PRA group was found to have 175 unique proteins and shared 67 proteins with
the inactive Rab5 (Rab5-GDP) control group and 5 proteins with the active Rab5 (Rab5GTP) control group (Figure 4a). In focusing on the proteins unique to the PRA-Rab5WT
group that were not found in the control Rab5 groups, many of the proteins
differentially unregulated and recruited on Rab5 endosomes fell into families of general
inflammatory mediators such as in the Type 1 IFN response family, IL-12 signaling
family, and IL-6 signaling family (Figure 4b). Other proteins were found to be related to
vesicle trafficking pathways such as clathrin-mediated endocytosis signaling and
secretory vesicle proteins, indicating a likely increase in vesicle transport in the PRARab5WT group (Figure 4b). The top family that was differentially unregulated and
recruited in the PRA-Rab5WT group compared to control groups, however, was the
SMAD-Associated Signal Activation proteins, or proteins associated with the TGF-ß
pathway (Figure 4b). Alongside this strong positive differential presence of TGF-ß
family proteins on Rab5 endosomes in DSA-induced complement fixation states, it is
again noted from prior literature (above-mentioned) that the DSA-mediated
complement pathway utilizes SMURF2, a known TGF-ß signaling protein, suggesting a
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link between these two seemingly divergent pathways. Preliminary analysis performed
from the proteomics screen furthermore confirmed increased amounts of TGF-ß family
proteins on Rab5 endosomes in the PRA-Rab5WT group compared to control groups
such as TGF-ß1, TGF-ß2, TGF-ßR2, BMP-R2, and SMAD proteins (Figure 4c).

As the TGF-ß family of proteins has been identified as a potential target of
interest that may serve effector functions in the DSA-mediated complement fixation
pathway, our aim moving forward focuses on showing that TGF-ß proteins follow the
two-step model described above of first being rescued from basal degradation by a
proteasome population and second being recruited to Rab5 endosomes to perform their
effector function.
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5.2 TGF-ß Signaling Components are Induced Following Antibody-Induced
Complement Fixation
In order to confirm the initial
results obtained by the proteomics
screen that DSA-mediated
complement fixation leads to
induction of TGF-ß components,
western blots of serial co-IPs of
Rab5 were performed following
PRA treatment of endothelial cells
at 0, 5, 15, and 30 minutes of both
previously described antibodyinduced complement signaling
pathway mediators such as
ZFYVE21, SMURF2, and NIK, as
well as proximal TGF-ß pathway
mediators including TGF-ßR2,
smad2, smad3, and the
phosphorylated smad 2/3 complex
(Figure 5).
In confirming prior studies describing DSA-induced complement signaling,
ZFYVE21 was found to be up-regulated on Rab5 endosomes within 5 minutes, leading to
subsequent increases in both SMURF2 as well as NIK, again displaying previously
described rapid induction of non-canonical NF-kB (Figure 5). Furthermore, proximal
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signaling effector proteins in the TGF-ß pathway including TGF-ßRII, smad2, smad3,
and the activated heterodimerized phosphorylated smad2/3 complex were all found to
be induced in a similar rapid timeframe as the antibody-induced complement signaling
pathway with sustained increase up to 30 minutes (Figure 5). Thus, antibody-induced
complement fixation is seen to lead to rapid induction of TGF-ß proximal effector
proteins in a similar timeframe as induction of the ZFYVE21-mediated pathway
activating non-canonical NF-kB through NIK.
In the case of antibody-induced complement fixation leading to up-regulation of
ZFYVE21 and downstream non-canonical NF-kB induction, a pan-proteasome inhibitor
MG132 was previously found to induce similar rescue of ZFYVE21 and associated
proteins leading to the hypothesis that there is basal degradation of antibody-induced
complement signaling pathway effectors by proteasomes. To test whether TGF-ß
proximal effector proteins are similarly degraded at baseline by proteasomes, we
performed similar experiments introducing MG132 at the same concentration to
endothelial cells and subsequently
performed serial western blots of proximal
TGF-ß pathway effector proteins (Figure
6). Again, similar to previously described
induction of ZFYVE21 and downstream
proteins, TGF-ßRII and smad2 were found
to be induced in endothelial cells within 30
minutes of treatment with MG132 and
sustained to at least 4 hours (Figure 6).
TGF-ßRI was found to be ubiquitously
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expressed as previously described in the literature and minimally affected by MG132
treatment (Figure 6). Thus, it appears that similar to ZFYVE21 and other antibodymediated complement signaling effectors described previously in the literature, TGF-ß
effector proteins are similarly degraded at baseline by proteasomes and, in the presence
of antibody-mediated complement fixation, are rescued from degradation.

5.3 Downstream TGF-ß Signaling Components are Post-Translationally Rescued from
Proteasomal Degradation and Proximal TGF-ßR2 is Post-Translationally Stabilized on
Activated Rab5 Endosomes
To further interrogate the dynamics of
TGF-ß superfamily proteins after posttranslational rescue from proteasomal
degradation and their relationship to Rab5
endosomes, we transduced HUVEC cells with
two different Rab5 constructs: Rab5 S43N
(dominant negative) and Rab5 Q79L
(constitutively active) (Figure 7). After
establishing these groups, we treated each with
pan-proteasome inhibitor MG132 which binds
to the 20S catalytic core, and performed serial
western blots over time (0, 1, 2, and 4 hours)
for ZFYVE21 (as an internal control) and
members of the TGF-ß superfamily of proteins including TGF-ßRII, smad2 and smad3
(Figure 7).
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As can be seen in both of the groups, the pan-proteasome inhibitor MG132
induced post-translational rescue of the downstream TGF-ß signaling components
SMAD2 and SMAD3 beginning at 1 hour after treatment sustained to 4 hours after
treatment (Figure 7). However, levels of both ZFYVE21 and TGF-ßRII were not seen to
be increased in the Rab5 dominant negative group treated with MG132 alone (Figure 7).
In comparison, in the constitutively active Rab579L group, both ZFVYE21 and TGF-ßRII
were found to be increased (Figure 7). From this, it can be deduced that while TGF-ßR2
and ZFYVE21 are both post-translationally rescued from proteasome degradation by a
pan-proteasome inhibitor, there may be a secondary requirement of being translocated
to Rab5-GTP or active Rab5 endosomes in order for them to be stabilized.
This combined with Figure 6 shows again the integral role that proteasomes
appear to play in the signaling modality that is induced by antibody-mediated
complement fixation.

5.4 The PA200 Proteasome Population is Selectively Inactivated by Antibody-Induced
Complement Activation
As discussed above in literature review, proteasomes are posited to have some
degree of specificity in the proteins that they target. Furthermore, it is noted in the
proteomics analysis performed at the outset that the proteins discovered in the MG132Rab5-GTP group (pan-proteasome inhibitor and constitutively active Rab5) did not
entirely overlap with the PRA-Rab5 group (Figure 4a, 4c) suggesting that a specific
proteasome population is selectively inactivated in the presence of antibody-induced
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complement fixation. In order to
interrogate whether there is
selective inactivation of
proteasome populations by
antibody-induced complement
activation, cells treated with PRA
underwent serial co-IP over time
(0, 5, 15, 30, and 60 minutes)
using a common core proteolytic
element PSMA2, and western
blots were performed to identify
specific proteasome populations
of interest (Figure 8). Co-IP was
performed using the common
core component PSMA2 in order
to ensure internal validity by normalizing the levels of proteasomes sampled over time.
From this, it is noted that two components that confer specificity to the PA200
proteasome population, PSME4 in row 1 (encoding the specific PA200 molecule that
binds to and affects proteasome function) and PSMD3 in row 2 (a regulatory 26S
subunit on the cap of proteasomes), are selectively inactivated within 5 minutes of PRA
treatment, while levels of other proteasome population lid elements in rows 3-7 are
stable up to one hour following PRA treatment (Figure 8). This finding serves to suggest
that antibody-induced complement activation specifically targets the PA200 population.
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5.5 The PA200 Proteasome Basally Degrades ZFYVE21 Effector Proteins and TGF-ß
Signaling Molecules
While antibody-induced complement signaling appears to specifically target the
PA200 proteasome population for degradation, attention then was turned to whether
the PA200 proteasome population
indeed targets and degrades antibodymediated complement signaling
pathway mediators such as previously
described ZFYVE21 mediators as well as
our newly found TGF-ß superfamily
proteins.
In order to confirm that the
PA200 proteasome targets components
induced by antibody-mediated
complement fixation, we knocked down
a PA200 proteasome lid element via
siRNA of the PSMC2 gene in the
presence and absence of PRA and
performed western blots of ZFYVE21
mediators and proximal TGF-ß pathway
mediators (Figure 9). In order to
confirm knock-down of PSMC2 with the
siRNA, PSMC2 was blotted in Row 8
indicating partial, but not complete
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knock-down in the PSMC2 siRNA groups as compared to the control siRNA groups
(Figure 9). When comparing lanes 1 and 2 in the non-PRA-treated group, it is observed
that ZFYVE21 and its downstream effectors as well as TGF-ß pathway effectors all
increase in the presence of the proteasome lid knockdown group compared to the
control siRNA group (Figure 9). A similar increase can be seen when one compares
lanes 3 and 4 in the PRA-treated groups (Figure 9). Specifically, ZFYVE21, SMURF2,
NIK, and Rubicon in the ZFYVE21 pathway induced by antibody-mediated complement
fixation and TGF-ßRII, smad2, and smad3 in the TGF-ß superfamily of proteins were
found to increase in the proteasome knockdown group compared to controls in both
physiological and PRA-treated settings (Figure 9). It is also noted that when one
compares the control groups to the PRA groups, there were increases in proteins from
both the ZFYVE21 pathway as well as TGF-ß pathway (specifically by comparing lanes 1
and 3 and 2 and 4) (Figure 9).
Last, of note is that the level of PSMC2 appears to have been unaffected by PRA
treatment, potentially indicating the lid component of the PA200 proteasome remains
intact, but unable to associate with the PA200 proteasome or perform effector function
(Figure 9). The idea that these lid components dissociate from the core proteasome
element is supported from data shown in Figure 8 as, following PRA treatment, the lid
elements PSME4 and PSMD3 are no longer found to be pulled down with core element
PSMA2 in co-IP studies.

5.6 PA200 Proteasome Components are Recruited to Rab5+ Endosomes
In further exploring the PA200 proteasome dynamics in relation to the Rab5
endosomes where antibody-mediated complement signaling proteins appear to localize,

35 of 53

attention was turned to whether or not proteasome components are recruited to Rab5
endosomes at baseline or whether they translocate following antibody-mediated
complement fixation. From the proteomics screen, when comparing constitutively active
Rab5 endosomes (Rab5-GTP), constitutively active Rab5 endosomes with MG132 panproteasome inhibitor treatment, and wild-type Rab5 treated with PRA, numerous
proteasome components are seen to be upregulated on Rab5 endosomes in endothelial
cells treated with PRA compared to cells with constitutively active Rab5 or with
constitutively active Rab5 with proteasome inhibitor MG132 (Figure 10a). This suggests
that antibody-induced complement fixation differentially recruits proteasome elements
onto Rab5 endosomes. However, as noted again in Figure 8, specific components of the
PA200 proteasome are not found to be associated with functional core PSMA2
proteasome components following PRA treatment, indicating that apparent recruitment
of lid components does not equate to proteasome function.
Furthermore, when performing serial co-IP of the proteasome lid component
PSMC2 and blotting for signaling proteins induced by antibody-induced complement
fixation, it is seen that over time there are increases in Rab5, TGF-ßRII, and ZFYVE21
after PRA treatment (Figure 10b). Increase in Rab5 co-localization with PSMC2 after
PRA treatment shown in row 1 once again points towards recruitment of the PSMC2 lid
component to these Rab5 endosomes and increase in TGF-ßRII and ZFYVE21 reaffirms
previously described co-localization on the Rab5 endosome in rows 2 and 3 (Figure
10b). Presence to some degree of TGF-ßRII and ZFYVE21 at time 0 in rows 2 and 3 with
PSMC2 could further be indicative of these proteins bound to PSMC2 destined for
degradation, but prior to entering the proteasome core element to be fully degraded
(Figure 10b).
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6. Discussion:
The present work aims to establish the TGF-ß superfamily of proteins as a
potential component in the pathogenesis of cardiac allograft vasculopathy induced by
DSA-mediated complement fixation as well as study more generally the mechanism by
which antibody-mediated complement fixation leads to rapid signaling changes, such as
leading to activation of non-canonical NF-kB (and subsequently canonical) as previously
described in the ZFYVE21 pathway.42
As ZFYVE21 and its downstream mediators were found to localize to Rab5
endosomes following antibody-mediated complement fixation, we hypothesized initially
that the previously described landscape of protein makeup on Rab5 endosomes in
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homeostatic conditions differed from the proteins recruited to Rab5 endosomes
following a stressor such as antibody-mediated complement fixation. Thus, in order to
elucidate or search for those differences, we grouped HUVEC cells into five different
conditions/treatments reflecting homeostatic vs non-homeostatic conditions and
performed co-IPs of Rab5 in order to capture early Rab5 endosomes and sent the eluted
peptides of the endosomes for proteomic analysis. The five groups we chose included
HUVEC cells with constitutively inactive Rab5 under homeostatic conditions,
constitutively active Rab5 under homeostatic conditions, constitutively active Rab5 with
pan-proteasome inhibitor MG132, constitutive active Rab5 with PRA treatment, and a
wild-type Rab5 with PRA treatment. Both the constitutively inactive and active Rab5
groups under homeostatic conditions served as controls in order to sample all the
proteins that would be recruited to early Rab5 endosomes. The MG132 group with
constitutively active Rab5 was meant to sample all the proteins that are rescued from
proteasomal degradation that have peptide motifs that would allow them to be
nonspecifically recruited to active Rab5 endosomes. The constitutively active Rab5
endosomes treated with PRA were meant to understand the specific sub-population of
proteins that are induced by antibody-mediated complement fixation and recruited to
active Rab5 endosomes and, through comparison with the Rab5 wild-type group treated
with PRA, one could deduce the proteins that are recruited to inactive Rab5 endosomes
treated with PRA. Finally, the wild-type Rab5 group with PRA treatment served to
closely mimic the proteins and signaling events occurring in antibody-mediated
complement fixation seen as one component causing CAV.
Classically, rigorous experimental design would necessitate the presence of a
wild-type Rab5 group under homeostatic conditions instead of a constitutively active
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and inactive Rab5 under homeostatic conditions in order to prevent the possibility of
confounding variables, however, the spectrum of proteins recruited to constitutively
active and inactive Rab5 endosomes under homeostatic conditions was seen as more
informative as a dual-control variable given the ability to sample all proteins in
homeostatic conditions that would be recruited to Rab5 endosomes, and would give
more insight down the road in terms of proteins that are differentially recruited in GTP
and GDP states. One must recognize, however, the potential confounding variable the
process of transfection of the HUVEC cells with gene constructs may cause in
inadvertently altering the landscape of signaling events. While there is no specific
literature discussing the role of transfection affecting the landscape of Rab5 endosomes,
transfection, whether it be viral (biological) or chemical has been theoretically proposed
to affect the cell.70,71 However, in the case of this study, all further analysis after the
proteomics screen was done with native HUVEC cells with or without PRA treatment.
Thus, there is greatest risk of a beta error, or missed signaling pathway, from this
proteomics screen as there may be proteins recruited to Rab5 endosomes in the control
groups that otherwise would not be without transfection.
Through this proteomics screen, we identified the TGF-ß superfamily of proteins
as being differentially upregulated on Rab5 endosomes as compared to homeostatic
conditions, pointing towards its role as an antibody-mediated complement pathway
mediator. As previously stated, the TGF-ß superfamily protein SMURF2 was previously
identified as playing a role in the ZFYVE21 pathway, hinting at the role that the TGF-ß
pathway may play in the greater signaling changes induced by antibody-mediated
complement.42 Furthermore, it is well described in the literature that proximal TGF-ß
receptors localize to and signal from early endosomes following clathrin-mediated
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endocytosis and a less clearly described lipid/caveolae-mediated endocytosis.72-75 Thus,
we decided to move forward with studying the TGF-ß superfamily of proteins in its
relation to antibody-mediated complement signaling.
In order to confirm the upregulation of TGF-ß component proteins on Rab5
endosomes following antibody-mediated complement fixation, western blots of co-IP of
Rab5 showed rapid induction of TGF-ß component proteins on Rab5 endosomes similar
to both previously described ZFYVE21 pathway mediators as well as repeat ZFYVE21
blots performed for the sake of internal validity.42 It was observed that within 5 minutes,
TGF-ß signaling components were upregulated on Rab5 endosomes. Furthermore, in
returning to our original hypothesis, these TGF-ß signaling components seem to follow a
similar “rapid induction” that would not be expected in the case of differential gene
expression leading to transcription and translation. Thus, in order to test the hypothesis
that TGF-ß signaling components follow closely with ZFYVE21 pathway mediators as
being rescued from a baseline proteasomal degradation, we treated HUVEC cells with
MG132, a pan-proteasome inhibitor in order to study whether or not these TGF-ß
mediators were basally transcribed, recruited to proteasomes, and degraded. Serial
western blots over time after MG132 treatment was notable for upregulation of TGF-ß
signaling components more firmly implying a role for proteasomes in the antibodymediated complement signaling as well as partially satisfying the first posit of our initial
hypothesis that inhibition of proteasomes leads to rapid upregulation of inflammationrelated proteins.
Next, we sought to test the conditions in which antibody-mediated pathway
proteins are recruited to Rab5 endosomes. We introduced pan-proteasome inhibitor
MG132 to cells with constitutively inactive Rab5 and constitutively active Rab5. From
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this, we found that the level of downstream smad2/3 in the TGF-ß signaling pathway
were all rescued from basal degradation in both groups irrespective of Rab5 status.
However, ZFYVE21 and TGF-ßRII were both only found to be upregulated in the
constitutively active Rab5 group (Rab5-GTP), implying a prerequisite Rab5-GTP state
for these proteins to be stabilized. The levels of smad2/3 being elevated irrespective of
Rab5 endosome status is not surprising given they are not classically described as
signaling from endosomes, whereas TGF-ßRII, being a membrane protein receptor, is
described as functioning from an endosomal base, similar to ZFYVE21.42,72-75
As non-specific inhibition of proteasomes leading to up-regulation of TGF-ß
signaling components suggests a post-translational mechanism of antibody-mediated
complement signaling, we sought to identify the specific proteasome population that
was targeted in antibody-mediated complement signaling as it is both unlikely that
antibody-mediated complement signaling shuts down the proteasome function entirely
in a cell and the proteomics screen we initially performed found differential protein upregulation in the MG132-treated constitutively active Rab5 group and the PRA-treated
constitutively active Rab5 group, as well as compared to the PRA-treated wild-type
Rab5 group. In order to interrogate the specific lid components that are targeted by
antibody-mediated complement signaling, we pulled down a common core proteolytic
component and western blotted for specific proteasome components that were
representative of different proteasome populations, ultimately finding the PA200
proteasome population as being selectively inactivated by PRA treatment. This finding
suggested that antibody-mediated complement fixation leads to selective degradation or
targeting of the PA200 proteasome population, making it a proteasome population of
interest.
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However, to show that the PA200 proteasome population selectively targets
antibody-mediated complement signaling proteins including ZFYVE21 and TGF-ß
superfamily proteins, we needed to show that the PA200 proteasome indeed targets
these pathway mediators. To show this, we transfected HUVEC with siRNA against a
PA200 proteasome lid component to knock-down PA200 proteasome function in order
to establish its role. One limitation of this strategy, seen in our western blot
confirmation of knock-down, was the limited efficiency of knock-down as compared to
other methods such as knock-out models. Namely, the PSMC2 lanes that were blotted
showed partial knock-down, but not complete. However, differences in levels of
ZFYVE21 mediators and TGF-ß mediators were still appreciated in the control siRNA
groups compared to the PSMC2 siRNA groups in both homeostatic as well as PRAtreated groups. In the future, different strategies can be employed in order to have
better knock-down efficiency with the PSMC2 siRNA in order to more clearly delineate
these differences. Thus, our siRNA studies established that the PA200 proteasome
population is implicated in targeting these antibody-induced complement signaling
mediators including ZFYVE21 pathway proteins as well as TGF-ß proteins. Combined
with the earlier co-IP studies of the proteasome core protein western blots, a pathway
can be deduced whereby antibody-mediated complement fixation leads to selective
inactivation of the PA200 proteasome population, further leading to inhibited
degradation of ZFYVE21 signaling proteins and TGF-ß proteins.
An interesting phenomenon noted through the siRNA knock-down studies
performed was the fact that PRA treatment, or antibody-mediated complement fixation,
did not lead to breakdown of the PSMC2 lid component, instead, led to disruption of its
proteasome function as evidenced by post-translational rescue of ZFYVE21 and TGF-ß
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pathway mediators. This finding implies that the lid components themselves are not
targeted for destruction, but rather are either unable to associate with the core
proteolytic proteasome elements or are in some way disrupted from their binding
capacity. Again, when looking at the core PSMA2 co-IP experiments, it would appear
that the core proteolytic element is dissociated from the PA200 lid components
following antibody-mediated complement fixation, leaving proteasome lid components
bound to ZFYVE21 and TGF-ß mediators.
In order to determine the spatial relationship that these proteasome components
have to the Rab5 endosomes that ultimately serve as the platform for previously
described antibody-mediated complement signaling via ZFYVE21, we turned back to our
initial proteasomal analysis that were performed on the Rab5 endosomes, specifically
comparing the untreated Rab5 constitutively active group, the pan-proteasome MG132treated Rab5 constitutively active group, and the PRA-treated Rab5 wild-type group and
noted numerous proteasome components were differentially recruited to Rab5
endosomes in the PRA-treated group. Furthermore, when pulling down for a
proteasomal lid component PSMC2 and blotting for Rab5 and other antibody-mediated
complement signaling mediators after PRA treatment, we found increased associations
of the proteasomal lid component PSMC2 with all of the above, suggesting that PRA
treatment leads to recruitment of this PA200 lid component to Rab5 endosomes, likely
while carrying ZFYVE21 and TGF-ß pathway proteins originally destined for
degradation. It was also noted that at time 0 during the co-IP, the PSMC2 lid
component was already found to be bound to some amount of ZFYVE21 and TGF-ß
pathway proteins, likely indicating active degradation.
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Taken all together, these experiments serve to suggest that proteasomes do not
simply function to basally degrade antibody-mediated complement signaling proteins
such as ZFYVE21 and TGF-ß proteins while under homeostatic conditions, but also
potentially serve a second role as a chaperone in bringing these pathway mediators to
the correct platform of Rab5 endosomes in order to perform their effector function. In
other words, at baseline, the PA200 lid components bind to ZFYVE21 and TGF-ß
signaling proteins and are associated with proteasomal core components that lead to
degradation. However, upon introduction of antibody-mediated complement fixation,
the PA200 lid components are dissociated from their core proteolytic element and are
instead translocated to Rab5 endosomes, bringing their cargo (ZFYE21 and TGF-ß
signaling proteins) along with them to ensure proper co-localization for further
downstream signaling changes.

To summarize briefly and recap at this stage, we have shown that for antibodymediated complement fixation, the TGF-ß superfamily of proteins follows in our
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proposed two-step model. Namely, we have shown that inhibition of proteasomes leads
to rapid upregulation of TGF-ß components and have more specifically shown a role for
the PA200 proteasome population as mediating this effect. Furthermore, we have
shown that after rescue from basal degradation by proteasomes, these proteins are
recruited via PA200 proteasome lid components to Rab5 endosomes which serve as a
platform for further downstream signaling. This would suggest that the same
proteasome components that specifically target these pathway mediators for
degradation under homeostatic conditions may dually serve a novel chaperone function
in aiding recruitment to the proper signaling platform. In this updated model,
proteasomes may serve as a stress sensor and chaperone. In basal homeostatic states,
they degrade pro-inflammatory proteins. However, with introduction of a stressor such
as antibody-mediated fixation of complement, proteasomes bound to pro-inflammatory
proteins are recruited to Rab5 endosomes and disassembled, bringing their proinflammatory mediators along in the process in order for them to co-localize and
perform downstream signaling function. Through this, cells are able to rapidly adapt
and respond to stressors without undergoing the typical process of transcription and
translation.
Through identification of the proteasome as being potentially central in the
pathogenesis of antibody-mediated complement signaling and one arm of allograft
vasculopathy, one may turn towards the clinical correlate in potential drugs targeting
proteasomes. Interestingly, as there is a well-described B-cell component to allograft
vasculopathy, efforts are already underway in studying the effect modulation of this
response has. Specifically, as described above in the literature review, the renal
transplant community has initiated the BORTEJECT Study, a Phase II study using
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bortezumib, a proteasome inhibitor, in preventing late allograft loss. Given the novel
findings that proteasomes may play in this pathway as described here, there may be a
dual function of preventing antibody-mediated complement signaling as well.
While we have been working up the more global mechanism by which we believe
antibody-mediated complement fixation leads to rapid signaling changes in endothelial
cells, we have also performed preliminary experiments in order to better characterize
the TGF-ß response that is induced through this pathway. Specifically, we have found
that antibody-induced complement activation generates TGF-ß1 and TGF-ß2 in
endothelial cells via ELISA in preliminary studies. We have also seen preliminary data
that TGF-ß signaling elicits endothelial cell activation via both RT-qPCR as well as TCell adhesion studies. Last, to better understand dynamics of co-localization, IHC would
be most informative in being able to observe the interactions between proteasome
components, ZFYVE21 and TGF-ß pathway mediators, and Rab5 endosomes pre- and
post-PRA treatment and those experiments are tentatively planned.
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7. COVID-19 Statement:
Much of the research presented was performed in the first year I was engaged in
the lab and my original plans were to resume research in the summer/winter 2020. As
much of the research involves physically being at the lab, these were disrupted as labs
were closed for much of the early summer. Moreover, my board exams, sub-internship,
and electives were all cancelled or pushed back during this time. In order to make the
most of my time then when my in-person activities were limited, I chose to engage in
research through reading in order to frame the work that is presented here as well as
focus more on thesis writing. When clinical electives and sub-internships were opened
again, I opted to complete those before returning to reading and thesis writing in order
to ensure I would be able to apply to residency this cycle.
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